CL2020003331A1 - Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 - Google Patents

Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2

Info

Publication number
CL2020003331A1
CL2020003331A1 CL2020003331A CL2020003331A CL2020003331A1 CL 2020003331 A1 CL2020003331 A1 CL 2020003331A1 CL 2020003331 A CL2020003331 A CL 2020003331A CL 2020003331 A CL2020003331 A CL 2020003331A CL 2020003331 A1 CL2020003331 A1 CL 2020003331A1
Authority
CL
Chile
Prior art keywords
inhibitors
cannabinoid receptor
pyrazine compounds
new pyridine
pyridine
Prior art date
Application number
CL2020003331A
Other languages
English (en)
Inventor
Uwe Grether
Luca Gobbi
Julian Kretz
Simon M Ametamey
Original Assignee
Hoffmann La Roche
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Eth Zuerich filed Critical Hoffmann La Roche
Publication of CL2020003331A1 publication Critical patent/CL2020003331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a un compuesto de fórmula (I); en donde A1, A2, X y R1-R3 son como se definen en la descripción y en las reivindicaciones. El compuesto de fórmula (I) puede usarse como un medicamento.
CL2020003331A 2018-06-27 2020-12-21 Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 CL2020003331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18180137 2018-06-27

Publications (1)

Publication Number Publication Date
CL2020003331A1 true CL2020003331A1 (es) 2021-05-07

Family

ID=62814868

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003331A CL2020003331A1 (es) 2018-06-27 2020-12-21 Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2

Country Status (18)

Country Link
US (1) US20210115011A1 (es)
EP (1) EP3814329B1 (es)
JP (1) JP7445610B2 (es)
KR (1) KR20210028202A (es)
CN (1) CN112262132A (es)
AU (1) AU2019294256A1 (es)
BR (1) BR112020025013A2 (es)
CA (1) CA3096777A1 (es)
CL (1) CL2020003331A1 (es)
CO (1) CO2020011855A2 (es)
CR (1) CR20200643A (es)
IL (1) IL279725B2 (es)
MA (1) MA53002A (es)
MX (1) MX2020012760A (es)
PE (1) PE20210368A1 (es)
PH (1) PH12020552152A1 (es)
SG (1) SG11202009103WA (es)
WO (1) WO2020002320A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
CA3235177A1 (en) 2021-10-28 2023-05-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
ATE407119T1 (de) * 2004-02-24 2008-09-15 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
CA2601575A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
DE602007006531D1 (de) * 2006-10-04 2010-06-24 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
US9303012B2 (en) * 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
PE20151060A1 (es) * 2012-12-07 2015-07-25 Hoffmann La Roche Nuevos derivados de pirazina como agonistas del receptor cb2
WO2015150438A1 (en) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
CA2943013A1 (en) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists

Also Published As

Publication number Publication date
CR20200643A (es) 2021-05-11
CA3096777A1 (en) 2020-02-02
JP2021529157A (ja) 2021-10-28
WO2020002320A1 (en) 2020-01-02
KR20210028202A (ko) 2021-03-11
PH12020552152A1 (en) 2021-07-05
US20210115011A1 (en) 2021-04-22
JP7445610B2 (ja) 2024-03-07
CN112262132A (zh) 2021-01-22
CO2020011855A2 (es) 2020-10-20
SG11202009103WA (en) 2020-10-29
PE20210368A1 (es) 2021-02-26
AU2019294256A1 (en) 2020-09-24
IL279725B2 (en) 2024-04-01
EP3814329B1 (en) 2024-01-17
IL279725A (en) 2021-03-01
BR112020025013A2 (pt) 2021-03-23
MA53002A (fr) 2021-05-05
MX2020012760A (es) 2021-03-25
IL279725B1 (en) 2023-12-01
EP3814329C0 (en) 2024-01-17
EP3814329A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
UY37623A (es) Derivados de oxadiazol tiofeno fungicidas
CL2020003331A1 (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
CR20180547A (es) Piridinas sustituidas con heteroarilo y métodos de uso
UY36999A (es) Derivados de aryl oxadiazol fungicidas
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
BR112018012390A2 (pt) derivados de oxadiazol microbiocidas
BR112018012378A2 (pt) derivados de oxadiazol microbiocidas
BR112018008467A2 (pt) derivados de oxadiazol microbiocidas
BR112019001229A2 (pt) derivados de oxadiazol microbiocida
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
BR112018012825A2 (pt) derivados de oxadiazol microbiocidas
BR112018074943A2 (pt) derivados de oxadiazol microbiocidas
BR112019000942A2 (pt) derivados de oxadiazol microbiocida
BR112018012338A2 (pt) derivados de oxadiazol microbiocidas
CO2019011967A2 (es) Compuestos antitumorales
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
UY37912A (es) Derivados de picolinamida fungicidas que portan grupos terminales heteroarilo o heteroariloxi
CR20160448A (es) Nuevos derivados de piridina